Skip to content

Ibogaine: all studies

Page 39 of 61: studies 381 to 390 of 610, newest first. Back to the ibogaine overview

Research

A preliminary investigation of ibogaine: case reports and recommendations for further study.

Journal of Substance Abuse Treatment 1994 S G Sheppard 162 citations

A naturally occurring substance, ibogaine, was taken by seven individuals who were addicted to opiates. Ibogaine, an alkaloid with psychotropic effects at doses of 200-300 mg and above, was taken in single doses of 700-1800 mg by the subjects in the study. At the end of the 24-38-hr psychoactive period induced by the drug at these doses, none of the subjects displayed significant opiate...

Local effects of ibogaine on extracellular levels of dopamine and its metabolites in nucleus accumbens and striatum: interactions with D-amphetamine.

Brain Research November 19, 1993 Stanley D Glick, K Rossman, S Wang et al. 38 citations

Systemic administration of ibogaine (40 mg/kg, i.p.) has been reported to induce both acute (1-3 h) and persistent (19-20 h) changes in extracellular levels of dopamine and its metabolites in the nucleus accumbens and striatum. In the present study, local administration of ibogaine to the striatum and nucleus accumbens produced effects that mimicked both the acute and persistent effects of...

Comparison of the behavioral effects of ibogaine from three sources: mediation of discriminative activity.

European Journal of Pharmacology November 2, 1993 M D Schechter, T L Gordon 33 citations

Ibogaine is an alkaloid employed for its hallucinatory properties in West Central Africa which has been the subject of alleged efficacy as an aid in the interruption and treatment of chemical dependency. The major sources of the Schedule I agent are: Sigma Chemical Co., the National Institute on Drug Abuse and as NDA International Inc.'s Endabuse. The intent of the present study was to, for the...

Inhibitory effects of ibogaine on cocaine self-administration in rats.

European Journal of Pharmacology September 14, 1993 S L Cappendijk, M R Dzoljic 176 citations

In order to determine the potential anti-addictive properties of ibogaine, we used the cocaine self-administration model in rats. The results indicate that a single injection of ibogaine (40 mg/kg i.p.) produced a significant decrease of cocaine intake, which remained unaltered for more than 48 h. Since the half-life time of ibogaine is short, this might suggest the involvement of one or...

Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline.

Neuroscience July 1, 1993 E O'Hearn, M E Molliver 220 citations

The indole alkaloids ibogaine and harmaline are beta-carboline derivatives that cause both hallucinations and tremor. Reports that ibogaine may have potent anti-addictive properties have led to initiatives that it be tested for the treatment of opiate and cocaine addiction. In this study, ibogaine-treated rats were analysed for evidence of neurotoxic effects because human clinical trials of...

ChemInform Abstract: Structure of Ibogaine.

ChemInform March 2, 1993 M. Soriano-García

Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.

DOI: 10.1002/chin.199309238 (opens in new tab) Nanotechnology Combinatorial chemistry Alkaloids

Ibogaine induces glial activation in parasagittal zones of the cerebellum.

Neuroreport March 1, 1993 E O'Hearn, D B Long, M E Molliver 72 citations

Ibogaine, an indole alkaloid, has been proposed for treatment of drug addiction, yet its mechanism, site of action, and possible neurotoxicity have not been determined. Since neuronal injury is known to activate neurologlial cells, we investigated potential neurotoxic effects of this drug in rats by examining expression of specific glial markers. After treatment with ibogaine (100 mg kg-1 i.p.;...

Stimulus effects of ibogaine in rats trained with yohimbine, DOM, or LSD.

Pharmacology, Biochemistry, and Behavior December 1, 1992 P A Palumbo, Jerrold C Winter 26 citations

The stimulus effects of ibogaine were compared with those of yohimbine, an alpha 2-adrenoceptor antagonist, 2,5-dimethoxy-4-methylamphetamine (DOM), a 5-hydroxytryptamine2 (5-HT2) agonist, and lysergic acid diethylamide (LSD), a nonspecific 5-HT agonist. Rats were trained with either yohimbine (6 mg/kg), DOM (0.6 mg/kg), or LSD (0.1 mg/kg) vs. no treatment in a two-lever discrimination task....

Structure of ibogaine

Acta Crystallographica Section C Crystal Structure Communications November 15, 1992 M. Soriano-García 2 citations

C 20 H 26 N 2 O cristallise dans P2 1 2 1 2 1 avec a=10,485, b=16,892, c=19,750A, Z=8; affinement jusqu'a R=0,073. Dans les deux molecules cristallographiquement independantes, le cycle a sept chainons est dans une conformation bateau. Le plan moyen passant par les atomes C(5)-N(6)-C(19)-C(2) de l'axe central de la structure tricyclique isoquinuclidine et le plan du cycle indole sont inclines...

Differential effects of ibogaine pretreatment on brain levels of morphine and (+)-amphetamine.

Brain Research August 14, 1992 Stanley D Glick, C A Gallagher, L B Hough et al. 21 citations

Previous studies in rats have shown that ibogaine inhibits neurochemical and behavioral effects of morphine yet potentiates similar effects of (+)-amphetamine. To assess whether these different functional interactions have a metabolic basis, brain levels of morphine and (+)-amphetamine were measured by gas chromatography-mass spectrometry after ibogaine pretreatment (19 h before injection of...